New Hope for Inherited Retinal Diseases as Lyora Therapeutics Launches
PROVIDENCE, RI – The inherited retinal disease (IRD) community has new reason for optimism with the official launch of Lyora Therapeutics. The biotech company is dedicated to developing genetic medicines that target the root causes of IRDs, conditions that often lead to progressive vision loss and currently lack available treatments. This news is particularly significant for patients and families navigating the challenges of IRDs, as it signals renewed focus and investment in potential new therapies.
Lyora Therapeutics announced its public launch on July 14, 2026, alongside the news that it has secured $2.5 million in pre-seed funding. This funding is intended to propel its pipeline of